http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022315915-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3164a963ca21cec1151213cb1bb95e77 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-04002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-90 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-902 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-102 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-04002 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 |
| filingDate | 2020-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2138cc25d8f1216cbb6c8358b2ac175 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a5f8c544d55d74505ea023fe54d0061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a95d63e357b47b709c62b1d9c0baf2fa |
| publicationDate | 2022-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022315915-A1 |
| titleOfInvention | Cytosine base-editing composition and use of same |
| abstract | The present invention relates to a cytosine base-editing composition, and more specifically, to a cytosine base-editing composition comprising adenine deaminase and CRISPR-associated protein 9 (Cas9), or functional analogs thereof, which has a narrow editing window and thus is capable of accurately editing cytosine in a target sequence with another base.The present inventors have discovered that the application of the cytosine base-editing composition comprising adenine deaminase and Cas9, or functional analogs thereof, to a target sequence, causes cytosine on a specific motif to be substituted with another base, and that existing adenine base editors (ABEs) are capable of editing not only adenine but also cytosine, and can also have said substitutions occur with higher accuracy compared to existing cytosine base editors (CBEs). Thus, the cytosine base-editing composition according to the present invention is expected to be advantageously used in the treatment of genetic disorders and in research on genetic disorders. |
| priorityDate | 2019-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 264.